Clene Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Clene Inc. (CLNN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.04M, a 23.92% decline year-over-year.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.31M, a 32.61% decline year-over-year.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.70M, a 22.17% decline year-over-year.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.37M, a 29.93% decline year-over-year.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.38M, a 19.75% decline from fiscal 2024.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.95M, a 12.77% decline from fiscal 2023.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.12M, a 7.10% increase from fiscal 2022.
- Clene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $8.51M, a 31.26% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04M 10-Q · filed 2026-08-14 | $2.35M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $1.31M 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $6.38M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-13 | $3.07M derived: sum of 2 quarters · filed 2026-08-14 | $5.02M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $1.37M 10-Q · filed 2026-08-14 | $3.31M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $1.95M 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $7.95M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $2.19M 10-Q · filed 2025-11-13 | $4.14M derived: sum of 2 quarters · filed 2025-11-13 | $6.15M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.95M 10-Q · filed 2025-11-13 | $3.96M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $2.01M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $9.12M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $2.40M 10-Q · filed 2024-11-13 | $4.85M derived: sum of 2 quarters · filed 2024-11-13 | $7.07M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $2.45M 10-Q · filed 2024-11-13 | $4.67M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $2.22M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $8.51M 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $2.10M 10-Q · filed 2023-11-07 | $4.28M derived: sum of 2 quarters · filed 2023-11-07 | $6.48M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.18M 10-Q · filed 2023-11-07 | $4.39M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $2.20M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $12.38M 10-K · filed 2023-03-13 | |||
| 2021-09-30 | $2.42M 10-Q · filed 2022-11-07 | $6.68M derived: sum of 2 quarters · filed 2022-11-07 | $9.95M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $4.25M 10-Q · filed 2022-11-07 | $7.52M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $3.27M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $761.00K 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $209.00K 10-Q · filed 2021-11-08 | $383.00K derived: sum of 2 quarters · filed 2021-11-08 | $554.00K derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $174.00K 10-Q · filed 2021-11-08 | $345.00K derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $171.00K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $399.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |